RecruitingPhase 1Phase 2NCT06703177

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase IB/II Study of Safety, Tolerability and Efficacy of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

876 participants

Start Date

Feb 18, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adebrelimab Injection, a drug called Bevacizumab Injection, and others for people with advanced solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1826

SHR-1826

DRUGSHR-4642

SHR-4642

DRUGSHR-9839

SHR-9839

DRUGSHR-8068

SHR-8068

DRUGBevacizumab Injection

Bevacizumab Injection

DRUGFluorouracil Injection

Fluorouracil Injection

DRUGCalcium Folinate Injection

Calcium Folinate Injection

DRUGAdebrelimab Injection

Adebrelimab Injection

DRUGCapecitabine tablets

Capecitabine tablets, oral.

Locations(1)

Sun Yat-Sen university cancer center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06703177

Related Trials

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT0717291911 locations

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT0571955815 locations

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT074603758 locations